cytarabine ocfosfate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| arabinofuranosyl derivatives | 771 | 73532-83-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 20 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA MoA | N0000000233 | Nucleic Acid Synthesis Inhibitors |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000963 | Antimetabolites |
| MeSH PA | D000964 | Antimetabolites, Antineoplastic |
| MeSH PA | D000998 | Antiviral Agents |
| MeSH PA | D007155 | Immunologic Factors |
| MeSH PA | D007166 | Immunosuppressive Agents |
| FDA EPC | N0000175595 | Nucleoside Metabolic Inhibitor |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35221 | antimetabolite |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35705 | immunosuppressive agent |
| CHEBI has role | CHEBI:38068 | antimalarial |
| CHEBI has role | CHEBI:50249 | anticoagulant |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:233423 | antifibrotic agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 1.84 | acidic |
| pKa2 | 11.57 | acidic |
| pKa3 | 13.08 | acidic |
| pKa4 | 4.04 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 65093-40-5 | SECONDARY_CAS_RN |
| 3041 | RXNORM |
| C0089089 | UMLSCUI |
| AR3 | PDB_CHEM_ID |
| C061162 | MESH_SUPPLEMENTAL_RECORD_UI |
| 3I7U8R8NWC | UNII |
| 23671562 | PUBCHEM_CID |
| 372 | MMSL |
| 4526 | MMSL |
| d00201 | MMSL |
| 002649 | NDDF |
| 387511003 | SNOMEDCT_US |
| 89265009 | SNOMEDCT_US |
| C0010711 | UMLSCUI |
| CHEBI:135838 | CHEBI |
| DB00987 | DRUGBANK_ID |
| 6253 | PUBCHEM_CID |
| 1709 | INN_ID |
| 4018080 | VANDF |
| D003561 | MESH_DESCRIPTOR_UI |
| CHEBI:28680 | CHEBI |
Pharmaceutical products:
None